Ivermectin for malaria control in mass drug administration programmes

Affiliations

¹ Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria.
² Global Health Institute, University of Antwerp, Antwerp 2610, Belgium. Electronic address: robert.colebunders@uantwerpen.be.

Comment

Astrid Christine Erber et al. Lancet Infect Dis. 2022 Apr.

. 2022 Apr;22(4):449-450.

doi: 10.1016/S1473-3099(22)00152-9.

¹ Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria.
² Global Health Institute, University of Antwerp, Antwerp 2610, Belgium. Electronic address: robert.colebunders@uantwerpen.be.

No abstract available

Conflict of interest statement

We declare no competing interests.

Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia.
Dabira ED, Soumare HM, Conteh B, Ceesay F, Ndiath MO, Bradley J, Mohammed N, Kandeh B, Smit MR, Slater H, Peeters Grietens K, Broekhuizen H, Bousema T, Drakeley C, Lindsay SW, Achan J, D'Alessandro U. Dabira ED, et al. Lancet Infect Dis. 2022 Apr;22(4):519-528. doi: 10.1016/S1473-3099(21)00557-0. Epub 2021 Dec 15. Lancet Infect Dis. 2022. PMID: 34919831
Ivermectin for malaria control in mass drug administration programmes - Authors' reply.
Dabira ED, D'Alessandro U. Dabira ED, et al. Lancet Infect Dis. 2022 Apr;22(4):450-451. doi: 10.1016/S1473-3099(22)00156-6. Lancet Infect Dis. 2022. PMID: 35338869 No abstract available.